contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


iconovo-receives-a-us-patent-for-icocapr-that-strengthens-the-offering-for-more-customer-collaborations

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Iconovo operates in the medical technology sector. The company develops inhalers for medical use. The company's products are used in the treatment of asthma and coal, where the inhalers consist of powder-based medicine. The products are licensed and sold under various brands. In addition to product development, there is expertise in pharmaceutical formulation. The company was founded in 2013 and has its headquarters in Lund.

Iconovo

Iconovo AB (publ), which develops complete inhalation products for a global market, announces today that the U.S. Patent and Trademark Office has approved the company's application for design...

<div class="mfn-preamble"><p><strong>Iconovo AB (publ), which develops complete inhalation products for a global market, announces today that the U.S. Patent and Trademark Office has approved the company's application for design protection of the ICOcap® inhaler. Iconovo recently regained the global rights to sell and distribute ICOcap® from Stevanato Group and intends to intensify the marketing of the inhaler towards international pharmaceutical companies, while Stevanato Group will act as the exclusive contract manufacturer.</strong></p></div><div class="mfn-body"><p>The design protection that the US Patent and Trademark Office has now issued for ICOcap® is valid until May 2037. The inhaler is already protected by patents in Europe. ICOcap® is one of several inhaler platforms that form the basis of Iconovo's customer offering in contract development management (CDMO). Earlier this year, a collaboration project was initiated with Kiox Pharma to develop a new treatment based on ICOcap® for a rare but serious lung disease.</p><p>"The fact that we have obtained strong exclusivity protection for ICOcap® in the world's largest pharmaceutical market further strengthens the offering for generating additional collaborative projects with international customers based on our unique inhaler. In addition, it broadens the opportunities for direct sales of the inhalers", says Roger Lassing, Vice President Business Development at Iconovo.</p><p>ICOcap® is a patented capsule-based dry powder inhaler with a one-piece-design making it easy to use. It has a robust, unique easy-to-grip design, a patented integrated mouthpiece cover, and low inhalation resistance. A standard version of ICOcap® is available off-the-shelf with the same function and performance as the established inhalers Breezhaler® from Novartis and RS01 from Berry.</p></div><div class="mfn-footer mfn-contacts mfn-d2d9cfa41f27"><p><strong class="mfn-heading-1">Contacts</strong></p><hr><p><strong>Johan&nbsp;Wäborg, CEO</strong><br>+46 707 78 51 71<br><a rel="noopener" href="mailto:johan.waborg@iconovo.se">johan.waborg@iconovo.se</a></p></div><div class="mfn-footer mfn-about mfn-9fe143181dfd"><p><strong class="mfn-heading-1">About Iconovo</strong></p><hr><p>Iconovo (Nasdaq First North Growth Market: ICO) develops new inhaled medicinal products in collaboration with international pharmaceutical companies. The company provides several types of patent-protected inhalers that can generate significant commercial opportunities in the development of novel pharmaceuticals and vaccines and at patent expirations for established pharmaceuticals. The most advanced project is a generic version of the asthma and COPD product Symbicort® which is expected to reach the market in 2025. Iconovo plans to market this product in the Nordic region through its subsidiary Iconovo Pharma, while the company's partner Amneal Pharmaceuticals has the rights in other parts of Europe and the United States. Certified Adviser is Erik Penser Bank AB.</p></div><div class="mfn-footer mfn-attachment mfn-attachment-general"><p><strong class="mfn-heading-1">Attachments</strong></p><hr><p><a rel="noopener" href="https://storage.mfn.se/55c5a3ce-b07d-4744-a54b-0010ab1bb8fa/iconovo-receives-a-us-patent-for-icocap-r-that-strengthens-the-offering-for-more-customer-collaborations.pdf" class="mfn-generated mfn-primary">Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations</a></p></div>

Iconovo receives a US patent for ICOcap® that strengthens the offering for more customer collaborations